Terms: = Thyroid cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Treatment
4394 results:
1. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
2. Assessment of thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of fibrin sealant application in patients undergoing thyroidectomy: a systematic review and meta-analysis.
Zheng X; Wang F; Su YC; Xu CY; Wang MZ
BMC Surg; 2024 Apr; 24(1):122. PubMed ID: 38658932
[TBL] [Abstract] [Full Text] [Related]
4. PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Kuboki Y; Koyama T; Matsubara N; Naito Y; Kondo S; Harano K; Yonemori K; Yoh K; Gu Y; Mita T; Chen X; Ueda E; Yamamoto N; Doi T; Shimizu T
Cancer Med; 2024 Apr; 13(8):e6980. PubMed ID: 38651187
[TBL] [Abstract] [Full Text] [Related]
5. thyroid nodule rupture after radiofrequency ablation: case report and literature review.
Ferraro T; Sajid S; Hodak SP; Baldwin CK
Front Endocrinol (Lausanne); 2024; 15():1355383. PubMed ID: 38628591
[TBL] [Abstract] [Full Text] [Related]
6. Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.
Wang Z; Zong H; Liu W; Lin W; Sun A; Ding Z; Chen X; Wan X; Liu Y; Hu Z; Zhang H; Li H; Liu Y; Li D; Zhang S; Zha X
J Exp Clin Cancer Res; 2024 Apr; 43(1):112. PubMed ID: 38610018
[TBL] [Abstract] [Full Text] [Related]
7. Factors associated with non-completion of palliative radiotherapy for spinal metastasis in patients with terminal cancer: a retrospective study.
Tokiya R; Nakanishi K; Okawaki M; Yamamoto A; Yamamoto Y; Saisho S; Fukuda Y; Nishie H; Teramoto S; Miyaji Y
Ann Palliat Med; 2024 Mar; 13(2):249-259. PubMed ID: 38584473
[TBL] [Abstract] [Full Text] [Related]
8. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory thyroid cancer Treated with Lenvatinib.
Kim CA; Kim M; Jin M; Kim HK; Jeon MJ; Lim DJ; Kim BH; Kang HC; Kim WB; Shin DY; Kim WG
Endocrinol Metab (Seoul); 2024 Apr; 39(2):334-343. PubMed ID: 38572536
[TBL] [Abstract] [Full Text] [Related]
10. A Novel TSHR Gene Mutation in a Family with Non-autoimmune Hyperthyroidism.
Kufoof T; Luxford C; Kannangara K; Clifton-Bligh R; Donaghue KC
Med Arch; 2024; 78(2):154-158. PubMed ID: 38566871
[TBL] [Abstract] [Full Text] [Related]
11. Contents analysis of thyroid cancer-related information uploaded to YouTube by physicians in Korea: endorsing thyroid cancer screening, potentially leading to overdiagnosis.
Kang E; Ju H; Kim S; Choi J
BMC Public Health; 2024 Apr; 24(1):942. PubMed ID: 38566004
[TBL] [Abstract] [Full Text] [Related]
12. Radioactive iodine administration is not associated with improved disease-specific survival in classic papillary thyroid carcinoma greater than 4 cm confined to the thyroid.
Lee-Saxton YJ; Palacardo F; Greenberg JA; Egan CE; Marshall TE; Tumati A; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
Surgery; 2024 Jan; 175(1):215-220. PubMed ID: 38563429
[TBL] [Abstract] [Full Text] [Related]
13. Development and validation of a nomogram for predicting lymph node metastasis in ductal carcinoma in situ with microinvasion: A SEER population-based study.
Zhu K; Sui Y; Zhu M; Gao Y; Yuan Y; Sun P; Meng L; Dai J; Li Z
PLoS One; 2024; 19(4):e0301057. PubMed ID: 38557552
[TBL] [Abstract] [Full Text] [Related]
14. Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation.
Zhang K; Wang X; Wei T; Li Z; Zhu J; Chen YW
Front Endocrinol (Lausanne); 2024; 15():1347362. PubMed ID: 38544687
[TBL] [Abstract] [Full Text] [Related]
15. thyroid cancer Survival in the Multiethnic Cohort Study.
Abe JV; Park SY; Haiman CA; Cheng I; Le Marchand L; Hernandez BY; Wilkens LR
Int J Environ Res Public Health; 2024 Mar; 21(3):. PubMed ID: 38541323
[TBL] [Abstract] [Full Text] [Related]
16. Sonographic characteristics of diffuse sclerosing variant of papillary thyroid carcinoma with histopathological correlation: a preliminary study.
Li W; Wang Y; Gao L; Feng R; Lv K; Wu X; Yang X; Cai S; Wang H; Li J
Orphanet J Rare Dis; 2024 Mar; 19(1):136. PubMed ID: 38532506
[TBL] [Abstract] [Full Text] [Related]
17. Prediction of potential mechanisms of rhubarb therapy for colorectal cancer based on network pharmacological analysis and molecular docking.
Yang F; Li X; Zhang Y; Ren Y; Zhang J; Xiao K
Medicine (Baltimore); 2024 Mar; 103(12):e37477. PubMed ID: 38518016
[TBL] [Abstract] [Full Text] [Related]
18. [The association between baseline TPOAb and/or TgAb positivity and thyroid immune-related adverse events in patients with malignancies following treatment with immune checkpoint inhibitors].
Gao Y; Ye T; Wu LG; Xu Y; Wang X; Cheng XQ; Zhang YL; Wang YY; Fan XR; Zhao HT; Liu H; Chai XF; Zhang L; Wang MZ; Li NS; Lian XL
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(12):963-969. PubMed ID: 38514346
[No Abstract] [Full Text] [Related]
19. Disease control in patients with non-small cell lung cancer using pemetrexed: Investigating the best treatment strategy.
Takahara Y; Abe R; Sumito N; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Nishiki K; Nojiri M; Kato R; Shinomiya S; Oikawa T
Thorac Cancer; 2024 Apr; 15(12):987-993. PubMed ID: 38485287
[TBL] [Abstract] [Full Text] [Related]
20. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Kim DW; Chul Cho B; Pachipala K; Kim SW; Wang CL; Chang GC; Ahn MJ; Alvarez R; Chiu CH; Trigo J; Estival A; Karam SD; O'Brien C; Gowda H; Jiang H; Bauman JE
Lung Cancer; 2024 Apr; 190():107530. PubMed ID: 38471416
[TBL] [Abstract] [Full Text] [Related]
[Next]
